PR95580

NEW YORK, April 21, 2022 /PRNewswire=KYODO JBN/ --

    -- Terran to advance the development of two of Sanofi's Phase 3 CNS

       therapeutics

    -- Transaction includes worldwide exclusive rights for development and

       commercialization in all fields of use

Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to

the development of transformational therapeutics for neurological and

psychiatric diseases, has entered into an agreement with Sanofi S.A. ("Sanofi")

for worldwide exclusive rights to develop and commercialize two late-stage CNS

pipeline assets.

Logo - https://mma.prnewswire.com/media/1758607/terran_biosciences_Logo.jpg

These therapeutics generated 4 Investigational New Drug (IND) applications and

over 104 clinical studies involving more than 15,000 subjects across a number

of CNS indications.

Terran plans to quickly advance the development of these assets for

neurological and psychiatric indications, which include several novel

applications where there is a large unmet medical need. This transaction

represents the key next stage in the development of these promising assets.

The deal included an upfront payment as well as typical success-based

milestones and royalties. Specific financial terms of the deal were not

disclosed.

"We are grateful to the Sanofi team for entrusting us to continue the

development of these late-stage therapeutics, which we believe have the

potential to transform the paradigm in neuropsychiatry," stated Dr. Sam Clark,

Terran's Founder and CEO.

About Terran Biosciences, Inc.

Terran is a biotech platform company developing a portfolio of therapeutics and

technologies for patients with neurological and psychiatric diseases. Backed by

a number of life-science and tech investors, Terran has built a CNS-focused,

tech-enabled drug development platform, and is rapidly advancing of number of

late-stage assets, which include novel psychedelic-based therapeutics.

Terran Contact

Investor Relations:

ir@terranbiosciences.com

Media:

info@terranbiosciences.com

SOURCE  Terran Biosciences, Inc.